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 Recurrent pregnancy loss affects one to five percent of couples. This complication 
is traumatic for women and has psychological implications, including anxiety and 
depression. Increased monitoring and support – tender loving care – from clinicians has 
been shown to positively impact pregnancy outcomes during subsequent pregnancies in 
women with recurrent pregnancy loss. The affect of tender loving care on pregnancy 
outcomes and psychological distress is not entirely clear, however. We propose a 
randomized controlled trial to determine if these associations are statistically significant. 
Specifically, we will recruit women with any cause for early recurrent pregnancy loss and 
compare early pregnancy outcomes and levels of psychological distress between women 
who receive tender loving care during the first trimester and those who receive standard 
prenatal care. Data from this study will provide insight into the impact of tender loving 
care on pregnancy outcomes and psychological distress in this population and guide 
patient management.
 1 
CHAPTER 1:  INTRODUCTION 
1.1 Background 
1.1A Spontaneous Abortion 
 Spontaneous abortion (SAB) is the most common adverse event affecting 
pregnant women.1 SAB, also referred to as miscarriage or pregnancy loss, is the 
expulsion of a fetus before the pregnancy reaches 20 weeks of gestation, or prior to a 
fetal weight of more than 500 grams.2,3 The majority of pregnancy losses are early, taking 
place before 12 weeks of gestation, rather than late, taking place after 12 weeks.2,4-6 
Many studies have aimed to accurately estimate the rate of SAB in the general 
population, and it has been determined and widely recognized that about 15% of all 
clinically recognized pregnancies (identified by ultrasonography or histopathologic 
evaluation7) result in SAB.1,4,8-11 The true incidence of SAB is difficult to determine, 
however, because only 30-50% of conceptions result in clinically recognized 
pregnancies.11,12 Many women miscarry before they know that they are pregnant or 
before the establishment of a clinical pregnancy by ultrasound. Most first trimester SABs 
are the result of genetic abnormalities, which increase with advancing maternal age.13-15 
1.1B Recurrent Pregnancy Loss 
 Recurrent pregnancy loss (also referred to as recurrent miscarriage or recurrent 
SAB) as defined by the American Society for Reproductive Medicine and the American 
College of Obstetrics and Gynecology, is the failure of two or more clinically recognized 
pregnancies.7,16 This definition is not fully agreed upon, however; some argue that 
because two consecutive losses may occur by chance alone, three or more losses are 
necessary for the diagnosis of recurrent pregnancy loss (RPL).3,8,17-19 Evidence shows that 
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in women who have had two consecutive pregnancy losses, the prevalence of abnormal 
results for diagnostic testing does not differ when compared with women who have had 
three or more consecutive losses.20 Hence, it is recommended that couples be evaluated 
for RPL following two losses.16,20 
 A large-scale population-based epidemiologic study estimating the incidence of 
RPL in clinically recognized pregnancies has not been conducted. Current knowledge 
regarding the epidemiology of this diagnosis is based on widely recognized estimates.18 It 
is estimated that one to five percent of women experience RPL, with variation due to 
differing definitions of RPL and the ages of women included in the estimates.1,9,21-23 
 Maternal age and obstetrical history are important risk factors affecting a 
woman’s ability to carry a pregnancy. While most random SABs occur due to 
chromosomal abnormalities,14 chromosomal abnormalities are more commonly the cause 
for pregnancy loss in random SABs than they are in RPL when the maternal age is less 
than 36.24-26 SAB risk increases with maternal age, however, regardless of obstetrical 
history, and a woman’s risk of pregnancy loss reaches 75% at the age of 45.27-29 This is 
likely due to oocyte chromosomal abnormalities.30 Previous obstetrical history is another 
risk factor for RPL. A woman’s risk of pregnancy loss may increase directly with each 
prior loss.5,28,29,31,32  
 Women with a history of RPL are commonly seen in specialty clinics and 
undergo extensive evaluations in attempts to uncover the cause for their losses.6,16 The 
etiology of RPL may be attributed to uterine anatomic abnormalities,33-38 immunological 
factors,39,40 endocrine disorders,41-45 genetic abnormalities14,15,26,46,47 and infection.48 The 
most common diagnosis given to women with RPL, however, is unexplained or 
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idiopathic RPL. More than 50% of women with RPL remain without a definitive 
explanation for their losses.6,15,27-29,49 
RPL is difficult to manage and treat because many of the etiologies are 
controversial and the efficacy of various treatment options is not entirely known. 
Treatment efficacy is difficult to ascertain because it cannot be known if a woman with a 
history of RPL is successful in carrying a subsequent pregnancy due to chance alone or 
treatment. Studies have shown that even women with unexplained RPL have up to a 60% 
chance of a future successful pregnancy depending on maternal age and parity status.27,28 
1.1C Psychological Implications of RPL 
 There are significant psychological implications for women with RPL. 
Miscarriage is a traumatic event for women and can induce anxiety, anger, dysphoria, and 
grief, emotions that can endure for several months.50 Pregnant women who have had 
prior miscarriages have been found to have higher levels of anxiety in subsequent 
pregnancies than pregnant women who have never had a miscarriage.51-53 Multiple 
studies have documented significant levels of anxiety and depression in women with RPL 
(higher than levels found in the general population), many of whom experience 
psychological symptoms that would likely warrant a psychiatric diagnosis if they were to 
be evaluated by a psychiatrist.54-58 Women with RPL may feel shame and guilt as a result 
of their difficulty in carrying a pregnancy, and they may doubt their reproductive ability, 
fearing that they will never have biological children, or never have another child. 
1.1D RPL and Tender Loving Care 
It is not entirely clear whether anxiety and distress are purely the result of RPL or 
if they are also mediators in the pathophysiology of RPL.57,59-61 Regardless, it is widely 
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recommended that women with a history of RPL receive increased emotional support and 
monitoring – termed supportive care or tender loving care (TLC) in the literature – during 
subsequent pregnancies.1,3,8,9,62-64 Women with RPL also report that they desire this 
advanced care.62,63 The recommendation for TLC is based upon the results of several 
studies suggesting that supportive care and close monitoring of a pregnancy from a 
dedicated team of healthcare providers may significantly increase the ability of a woman 
with a history of RPL to have a successful pregnancy.65-67 In one such study, successful 
pregnancy outcomes were documented in 86% of women who received TLC, as 
compared with 33% of women who did not receive the intervention.67 
1.2 Statement of the Problem 
Although the results of previous studies examining the impact of TLC on 
pregnancy outcomes in women with a history of RPL are compelling, questions remain 
regarding the efficacy of TLC in RPL patients. To date, a randomized controlled trial 
(RCT) has not been conducted in this area. As a result, the information that we have 
regarding the impact of TLC on women with RPL is subject to bias and confounding, and 
concrete data are lacking.61,68 Without random allocation of the intervention to study 
participants, it is difficult to calculate the impact that TLC has on pregnancy outcome. 
 In addition, previous studies looking at TLC and pregnancy outcomes in women 
with RPL exclude women who have been diagnosed with a known cause for RPL. 
Therefore, the data from these studies are not generalizable to all women with RPL – 
those with known etiologies for RPL and those with idiopathic RPL. 
 Although studies examining the impact of TLC on pregnancy outcomes in women 
with RPL use the terms TLC and supportive care, the terms are poorly defined and differ 
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between studies.65-67 Recommendations are made to treat RPL patients with TLC, but this 
is difficult when the term is variable and not clearly defined for patients and clinicians. 
TLC generally comprises some combination of continuity of care with the same medical 
staff, weekly ultrasounds to ensure fetal viability and offer reassurance, emotional 
support, partner involvement in care, formal psychotherapy and counseling, relaxation 
techniques, and recommendations regarding sexual intercourse, diet, and lifestyle during 
pregnancy.65-67,69,70 In order to best care for and manage RPL patients, it is necessary to 
clearly define TLC in the context of RPL by examining the literature to determine 
evidence-based practice and the preferences of women with the diagnosis of RPL. 
 Finally, although one study examined the impact that TLC may have on anxiety 
levels in women with RPL during a subsequent pregnancy, the study was a small 
prospective cohort study, and it only included women with idiopathic RPL.69 RPL is 
anxiety-inducing and frustrating for all women, and the difference in anxiety levels 
between women with idiopathic RPL and women with a known cause for RPL is not 
statistically significant.54,70 Therefore, it is valuable to study the impact that TLC may 
have on levels of psychological distress in women with explained and unexplained RPL. 
1.3 Goals and Objectives 
 The overall goal of this RCT is to assess the impact of TLC on pregnancy 
outcome at 12 weeks of gestation in women with a history of early RPL. Specifically, this 
study aims to determine if TLC does in fact improve early pregnancy outcomes in RPL 
patients by reducing the rate of SAB in subsequent pregnancies as described in previous 
literature. Additionally, this study aims to determine if TLC has an impact on the level of 
psychological distress in this population. 
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 This study will provide a better understanding regarding the specific impact of 
TLC on pregnancy outcomes in women with a history of RPL. Additionally, further 
insight will be gained into the role that TLC plays in mediating psychological distress in 
women with a history of RPL. 
1.4 Hypothesis 
 There is a 15% difference in early pregnancy outcome at 12 weeks of gestation 
among pregnant women with a history of early recurrent pregnancy loss who receive 
tender loving care during the first trimester of pregnancy when compared with women 
who receive standard prenatal care during the first trimester of pregnancy. 
1.5 Operational Definitions 
Pregnancy outcome:  presence or absence of an ongoing, viable pregnancy at 12 weeks of 
gestation, as determined by ultrasound. 
Recurrent pregnancy loss (RPL):  two or more consecutive pregnancy losses.7 
Tender loving care (TLC):  serial serum human chorionic gonadotropin (hCG) 
monitoring until the pregnancy can be visualized by ultrasound; weekly transvaginal 
ultrasound monitoring of pregnancy beginning at five weeks of gestation; well-defined 
and planned care for the first trimester; continuity of care from the same staff members at 
each visit; empathy and support from the staff and recognition of the woman’s emotional 
needs; partner engagement during visits; reassurance and feedback on the status of the 
pregnancy; time to ask questions, address concerns, and elicit advice appropriate to the 
gestation age of the pregnancy; availability of a social worker for counseling purposes; 
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 CHAPTER 2:  REVIEW OF THE LITERATURE 
2.1 Introduction 
 An extensive review of the literature took place between September 2013 and 
May 2014. The review took place to study the epidemiology and various etiologies of 
RPL. The etiologies of RPL and possible treatments were reviewed in order to 
comprehensively understand the population of women to be included in the proposed 
study, as well as to study the methodology employed when involving pregnant women 
with RPL in clinical studies. The literature review was also conducted to identify the 
psychological implications of RPL. Finally, the review took place to research the impact 
of TLC on pregnancy outcomes in women with RPL. The literature review revealed no 
RCT to date assessing the impact of TLC on pregnancy outcomes in women with RPL. 
 The Ovid MEDLINE database, Scopus, and the Cochrane Library were utilized 
for the search. Search topics included the following terms independently and in various 
combinations:  pregnancy loss, spontaneous abortion, habitual abortion, recurrent 
pregnancy loss, recurrent miscarriage, recurrent spontaneous abortion, anxiety, 
psychological impact, psychological adaptation, psychological stress, psychological 
support, supportive care, tender loving care, prenatal care, pregnancy monitoring, social 
support, pregnancy outcome, and treatment outcome. The search was limited to studies in 
English and those involving human subjects. Prospective trials, retrospective trials, 
RCTs, cross-sectional analyses, meta-analyses, and high-quality reviews were evaluated. 
2.2 Review of Relevant Studies 
 This section of the literature review will focus on previous studies that examine 
the relationship between TLC and pregnancy outcomes in women with RPL. The results 
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of these studies will form the rationale for the proposed study. This section will also 
review the literature discussing the psychological implications of pregnancy loss. These 
studies will provide the rationale for assessing psychological distress in the participants in 
the proposed study in order to determine if TLC has an impact on levels of psychological 
distress during the first trimester of subsequent pregnancies in women with RPL. 
 2.2A TLC and RPL:  Empirical Evidence 
 The literature review returned four studies examining TLC and its impact on 
subsequent pregnancies in women with RPL. Each of these four TLC studies examines 
the relationship between TLC and pregnancy outcomes in women with idiopathic or 
unexplained RPL. No studies examining the relationship between TLC and pregnancy 
outcomes in women with both known causes for RPL and idiopathic RPL were found. No 
large-scale RCT with sufficient power, examining the relationship between TLC and 
pregnancy outcomes in women with RPL, was found. 
 Stray-Pedersen et al. conducted a quasi-experimental prospective study examining 
the etiology of pregnancy loss and reproductive outcomes in couples with RPL. The 
study included 195 couples with a history of three or more consecutive pregnancy losses 
that were referred to the Department of Obstetrics and Gynecology (OB-GYN) at the 
National Hospital in Norway between 1971-1980. Couples underwent diagnostic testing, 
and abnormalities were identified as a probable cause for RPL in 56% of the couples. The 
couples were offered treatment and 80% of those who conceived carried their subsequent 
pregnancies to term.1 
 Of most pertinence to the proposed study is the group of 85 couples who were not 
diagnosed with a cause for RPL. Women in this group were told to notify the hospital 
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immediately upon becoming pregnant. Sixty-one (72%) of the couples became pregnant 
during the study. Those identified as living within a reasonable distance from the hospital 
(n=37) were selected for TLC, which included psychological support, weekly medical 
visits and exams, encouragement to rest, avoidance of heavy work and travel, abstinence 
from sexual intercourse, and bed rest for the two week gestational period during which 
they had experienced their previous losses. They were provided no surgical or medical 
treatment. The remainder of the women (n=24) did not receive specific antenatal care and 
were advised to attend their local antenatal clinic. The primary outcome variable was the 
success of a pregnancy (delivery of a healthy baby at term). Eighty-six percent of the 
women receiving TLC had successful pregnancies and 14% experienced pregnancy loss. 
In comparison, 33% of the women who did not receive TLC had successful pregnancies 
and 67% experienced pregnancy loss. Statistical analysis was performed using chi-square 
testing with Yate’s correctional factor. The 53% difference in successful pregnancy 
outcome between the groups was statistically significant (p<0.001).1 
 Although the results of the study conducted by Stray-Pederson et al. are 
statistically significant, a discussion of the study is warranted. The study only included 
couples with idiopathic RPL. Therefore, it is difficult to ascertain the impact that TLC 
might exert on couples with a known cause for RPL. Even in couples with a known 
etiology for RPL, it cannot be decided with certainty that the identified abnormality is the 
cause of RPL. In addition, the design introduces significant selection bias into the results, 
as couples were assigned to the intervention and control groups based on their distance 
from the hospital. Finally, TLC treatment was not optimally defined. It is unclear what is 
meant by and included in “optimal psychological support” and “weekly medical exams.”1 
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 Liddell et al. also examined pregnancy outcomes following TLC in a group of 
women with unexplained RPL (three or more unexplained losses). The prospective cohort 
study included 52 women, 42 of whom were selected to receive supportive care (TLC) at 
an early pregnancy clinic during the first trimester of subsequent pregnancies, and 10 of 
whom were assigned to attend a standard prenatal clinic. Supportive care consisted of the 
diagnosis of pregnancy at four to five weeks of gestation, weekly visits at an early 
pregnancy clinic (with hCG, progesterone, and ultrasound monitoring, during which the 
women were advised to view their embryo on the screen), continuity of care with the 
same medical staff, stress reduction and relaxation techniques (a weekly class teaching 
relaxation and daily use of a relaxation tape), consistent feedback on the progression and 
status of the pregnancy, and a specialized room at the hospital that the women could visit 
during the anniversary of previous losses or if their current pregnancy was in danger. 
They received no pharmacologic or surgical treatment. At the end of the first trimester, 
women in the intervention group were discharged to receive ongoing prenatal care from 
their own OB-GYN clinician. Women assigned to the control group did not receive 
specialized care and were advised to attend the clinic of their OB-GYN provider.2 
 In the group of women assigned to receive supportive care, 44 pregnancies were 
followed (two women attended the clinic for two pregnancies). Eighty-six percent of the 
pregnancies were successful (resulting in a live birth) and 14% resulted in miscarriage. In 
comparison, nine of the ten women in the control group became pregnant and 33% had a 
live birth. The 53% difference in successful pregnancy outcome between the groups was 
found to be statistically significant (p=0.005; statistical analysis by Fishers Exact Test).2 
 16 
 These results suggest a high rate of success in subsequent pregnancies in women 
with idiopathic RPL when they are offered supportive care alone during the first trimester 
of pregnancy. The study did not include women with an identified cause for RPL. 
Although the study included a randomization process and the groups were not found to 
vary at baseline in terms of average age, average number of recurrent losses, and primary 
vs. secondary RPL (primary RPL referring to those who have never had a live birth and 
secondary RPL referring to those who have had a live birth prior to recurrent losses), the 
randomization process is not described and it is not known how treatment groups were 
allocated. Finally, the women in this study knew which group they were assigned to 
before becoming pregnant. There was no concealment of group allocation prior to the 
subsequent pregnancy. As a result of unclear randomization techniques and a lack of 
allocation concealment, the results of this study may be affected by selection bias.2 
 Clifford et al. conducted a prospective cohort study examining the impact of 
supportive care on unexplained first trimester RPL and had similar findings. Women 
attending St. Mary’s Hospital’s recurrent miscarriage clinic in London underwent testing 
to identify the cause for RPL. Those diagnosed with unexplained first trimester recurrent 
miscarriage (three or more consecutive first trimester miscarriages) formed the study 
group (n=201). They were encouraged to attend an early pregnancy clinic during the first 
trimester of subsequent pregnancies, which included weekly ultrasounds to assess fetal 
viability and measure growth, and continuity of care with the same clinicians. They did 
not receive medical or surgical treatment prior to or during the pregnancy. The women 
who did not attend the clinic received no specialized care and were contacted by phone or 
mail to obtain information regarding the outcome of their pregnancy.3 
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 Of the women who attended the early pregnancy clinic (n=160), 74% had a 
successful pregnancy outcome (live birth) and 26% miscarried. Those who did not attend 
the clinic (n=41) had a successful pregnancy outcome of 49% and 51% miscarried. The 
difference in miscarriage rates between these two groups was statistically significant 
(25% difference; p=0.002). The group of 201 women experienced 63 total miscarriages, 
all of which occurred during the first trimester. This suggests that women with a history 
of early RPL will continue to miscarry during the first trimester in subsequent 
pregnancies. Women under 40 who had less than six prior miscarriages and who attended 
the early pregnancy clinic had the best prognosis, with a miscarriage rate of 21%.3 
  Although the women were not randomized to the groups, there was no 
statistically significant difference in the baseline characteristics (ethnicity, median age, 
and number of previous losses) of women who attended the pregnancy clinic and those 
who did not (p=0.5 for median age, p=0.7 for number of previous miscarriages). Lack of 
randomization, as in the other studies, may have introduced selection bias into the results, 
as women self-selected for treatment. The study group in this study was larger than in the 
other studies, but the intervention and control groups were unbalanced, with 160 women 
in the intervention group and only 41 women in the control group.3 
 Al-Otaibi et al. conducted a prospective cohort study that examined the impact of 
supportive care on anxiety levels and early pregnancy outcomes in women with RPL. 
Seventeen pregnant women (gestational age of nine weeks or less) with a history of 
unexplained first trimester RPL (three or more consecutive losses) were selected for 
study participation. Baseline characteristics were collected and included maternal and 
paternal age, level of education, occupation, number of previous pregnancies, number of 
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previous losses, number of living children, and gestational age. Anxiety levels were 
measured prior to and after the administration of supportive care using the Hamilton 
Anxiety Rating Scale.4 Each week, the women received ultrasounds to assess the fetal 
heart rate and measure fetal growth. Supportive care was comprised of sessions offering 
advice regarding diet and lifestyle, emotional needs, relaxation techniques, exercise, 
medication use, and warning signs of pregnancy loss. Early pregnancy outcome was 
defined as the presence of an ongoing pregnancy at 12 weeks of gestation on ultrasound.5 
 Eighty-eight percent of women had a successful early pregnancy outcome and 
12% miscarried. Study results revealed a reduction in anxiety symptoms after supportive 
care. Prior to supportive care, 35.3% of participants had severe anxiety, 52.9% moderate 
anxiety, and 11.8% mild anxiety. After supportive care, 93.3% had mild anxiety and 
6.7% had moderate anxiety. The results were statistically significant (p=0.001).5 
 This study is significant because it not only examines the link between TLC and 
pregnancy outcomes, but it also examines the impact that supportive care may have on 
anxiety in women with RPL. While the participants experienced a high rate of successful 
pregnancy outcome at 12 weeks of gestation and statistically significant reductions in 
anxiety, the study was a small observational study without a control group. This makes it 
difficult to determine if the outcomes are due to the impact of the intervention or if they 
are due to chance or bias. In addition, patients were eligible to enter the study at any time 
prior to nine weeks of gestation. These women did not receive assessment of anxiety or 
supportive care at the same time points during their pregnancies.5 
 The empirical studies examining the impact of TLC on pregnancy outcomes 
reveal the need for a RCT. Without a RCT, it is difficult to know the true effect of TLC 
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on pregnancy outcomes. A RCT will limit the impact of bias and confounding on study 
results. The study also needs to be adequately powered with a large sample size. The 
literature review reveals that TLC, or supportive care, varies between the studies, making 
it difficult to determine which components of TLC are most important or effective. 
 2.2B Psychological Implications of Pregnancy Loss 
 This portion of the review will focus on studies examining the psychological 
implications of SAB and RPL. This will provide the rationale for assessing psychological 
distress in women at the start and end of the proposed study to determine if TLC affects 
levels of psychological distress during subsequent pregnancies in women with RPL. 
 Tsartsara et al. examined the impact of miscarriage history on pregnancy-specific 
anxiety (Pregnancy Outcome Questionnaire6) and maternal fetal attachment (Maternal 
Antenatal Attachment Scale7) in pregnant women during their first and third trimesters. 
The study recruited thirty-five pregnant women, 71.4% with no history of miscarriage 
and 28.6% with a history of miscarriage. Marital status, age, pregnancy planning, 
gestational age, number of prior pregnancies, and parity were controlled for. In the first 
trimester of pregnancy, ANOVA revealed a statistically significant difference in 
pregnancy-specific anxiety levels between the groups (p=0.001). Pregnancy-specific 
anxiety was higher in women with a history of miscarriage, irrespective of parity status. 
However, differences in maternal fetal attachment scores were not found to be 
statistically significant (p=0.208, p=0.119, and p=0.952 for subscales). In the third 
trimester, anxiety levels were not significantly different between the groups (p=0.411). In 
addition, maternal fetal attachment was higher for both groups in the third trimester, with 
statistically significant differences from the first to the third trimester (p=0.01, p=0.004, 
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and p=0.000 for subscales). The data from this study suggest that women with a history 
of miscarriage experience higher levels of pregnancy-specific anxiety early in a 
subsequent pregnancy when compared with women with no history of miscarriage, 
regardless of whether or not the woman has a living child. The study also suggests that 
anxiety is highest in these women during the first trimester and decreases by the third.8 
 It is important to note that the two groups in the study were unequal in size, 10 
having a history of loss and 25 having no history of miscarriage. Selection bias may have 
affected study results, as only 24 of the original participants followed up during the third 
trimester, with 50% of the miscarriage group being lost to follow-up. It is not known if 
they dropped out of the study due to increased anxiety or a subsequent pregnancy loss.8 
A comparative descriptive cross-sectional study by Cote-Arsenault et al. sought to 
compare state anxiety, pregnancy specific anxiety, and optimism in multigravid women 
with and without a history of perinatal loss. The study recruited 160 multigravid pregnant 
women at 17-28 weeks of gestation, 96 with no history of perinatal loss, and 74 with a 
history of perinatal loss (early SAB to neonatal death). A self-administered questionnaire 
was utilized to collect demographic data, OB history, and utilization of healthcare during 
pregnancy. The women also completed the Spielberger State-Anxiety Inventory9 (used to 
asses state anxiety - subjective feelings of temporary anxiety), the Pregnancy Anxiety 
Scale (developed to assess pregnancy-specific anxiety), and the Life Orientation Test10 
(utilized to assess optimism). T-tests or chi square analyses were used to compare the 
groups, which were similar at baseline in regards to demographic variables and optimism 
(t=0.93, p>0.05). The difference in state anxiety between the two groups was not 
statistically significant (p=0.067). However, the difference in pregnancy-specific anxiety 
 21 
between the groups was statistically significant (p=0.003). In addition, women with 
higher levels of state and pregnancy anxiety reported greater utilization of healthcare, 
desiring more frequent phone calls and visits with their healthcare providers.11 
Of note, the women in this study were homogeneous, with the majority being 
highly educated, of middle to high socioeconomic status, married, employed, and 
Caucasian, creating a lack of external validity. Women in the loss group had diverse OB 
histories, with varying times during which they experienced losses (from two weeks of 
gestation to neonatal death, M=10.38 weeks, SD=6.93). Some of the women had losses 
prior to a live birth and some had losses after a life birth. Time since perinatal losses 
ranged from one to twelve years. With such variability in the loss group and the presence 
of covariates, it is difficult to ascertain the impact of perinatal loss on anxiety levels.11 
Hutti et al. conducted a longitudinal cohort study examining the impact of 
depression, anxiety, and perinatal loss on a woman’s utilization of healthcare during 
pregnancy. The study included 36 women with a history of perinatal loss, 32 women with 
no history of perinatal loss, and 38 women experiencing their first pregnancy. Data were 
collected from these women from the third trimester of pregnancy until eight months 
postpartum. Anxiety was measured using the Spielberger State-Trait Anxiety Inventory.9 
Women with previous perinatal losses had higher baseline levels of anxiety when 
compared with women in the other groups (p=0.008).12 This is interesting because 
Tsartsara et al. did not find anxiety to persist late in pregnancy in women with a history 
of perinatal loss.8 Tsartsara et al., however, assessed pregnancy-specific anxiety, whereas 
Hutti et al. assessed state and trait anxiety.8,12 Women were also asked to report their 
utilization of healthcare during the current pregnancy. During the third trimester, women 
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with a history of perinatal loss reported more phone calls to healthcare providers, 
unscheduled office visits, and diagnostic procedures than women in the other groups 
(p=0.013, p≤0.001, and p=0.005).12 
 Similar to those in the study by Cote-Arsenault et al., the participants in this study 
were homogenous, limiting the external validity of the study.11 In addition, recall bias 
may have impacted the study results, as women were asked to self-report their utilization 
of healthcare. Women may have under- or over-reported their utilization of healthcare.12 
 Blackmore et al. conduced a large cohort study assessing symptoms of anxiety 
(measured by the Crown-Crisp Experimental Index13) and depression (measured by the 
Edinburgh Postnatal Depression Scale14) in subsequent pregnancies in women with a 
history of perinatal loss. About 13,000 women with and without histories of perinatal loss 
were recruited and assessed numerous times during pregnancy and postnatally. The 
number of previous losses significantly predicted symptoms of depression (p<0.01) and 
anxiety (p<0.01), with psychosocial and OB factors controlled for. The association was 
found to persist throughout pregnancy and postnatally.15 These results support the 
findings of Hutti et al., suggesting that significant psychological symptoms may persist in 
women with a history of perinatal loss, even after the birth of a healthy child.12,15 
 In a cross-sectional study, Craig et al. examined the impact of RPL on 86 women 
attending a recurrent miscarriage clinic. Participants completed Beck’s Depression 
Inventory,16 the Spielberger Trait Anxiety Inventory,9 the General Health 
Questionnaire,17 and St. Mary’s Miscarriage Questionnaire (developed to assess 
pregnancy-specific psychiatric morbidity). Psychiatric morbidity did not differ 
significantly in women with a history of two pregnancy losses when compared to women 
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with a history of three or more losses (post hoc independent t-tests; p>0.1), suggesting 
that women with a history of two losses experience significant psychological symptoms. 
Thirty-three percent of women had depressive symptoms and 21% had significant levels 
of anxiety, regardless of parity, number of prior miscarriages, and time since last 
miscarriage. Regardless of obstetrical history, women may have significant psychological 
consequences of RPL up to 10 months after the last loss. This study did not utilize a 
control group, making it difficult to ascertain the significance of the study results.18 
  The above studies suggest that women with pregnancy loss experience significant 
psychiatric morbidity, which may persist late into a subsequent pregnancy and even into 
the postpartum period.12,15 Psychiatric morbidity is found in women with pregnancy loss 
regardless of parity and other obstetric factors.8,18 In addition, those with increased 
anxiety during pregnancy report greater utilization of healthcare.11,12 
2.3 Review of Possible Confounding Variables 
 A number of variables may impact a woman’s ability to successfully carry a 
pregnancy. Potential confounders to the association between TLC and early pregnancy 
outcomes in women with a history of early RPL will be discussed here. 
 2.3A Maternal Age 
 Maternal age significantly affects a woman’s ability to conceive and carry a 
pregnancy. The study by Clifford et al. found that women 30 and under had a miscarriage 
rate of 25% in subsequent pregnancies, but women 40 and over had a miscarriage rate of 
52% (p=0.02).3 A descriptive cohort study by Lund et al. examined prognostic factors for 
live birth in women with RPL. Only 42% of women 40 and older gave birth to a child 
within five years, compared to 81% of women aged 20-24 (p<0.01). Using women aged 
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30-34 as a reference group (HR=1), the HR of giving birth to a child during a five year 
period was 1.43 (95% CI, 1.03-1.98) for women aged 20-24 and 0.55 (95% CI, 0.36-
0.83) for women 40 and older.19 A population-based case-controlled study revealed a 
three-fold increased risk of miscarriage in subsequent pregnancies in women with a 
history of at least one miscarriage in women under 24 years of age (OR 2.9; 95% CI, 1.4-
5.8) and women over 35 years of age (OR 2.8; 95% CI, 1.1-6.8), when compared with 
women aged 24-34 (p<0.0001).20 Another population-based case-controlled study found 
that relative to women aged 25-29, women between the ages of 35 and 39 had a 75% 
increased risk of first trimester miscarriage (OR 1.75; 95% CI, 1.37-2.22) and women 40 
and over had a five-fold increased risk of miscarriage (OR 5.1; 95% CI, 3.54-7.52). No 
differences in miscarriage odds were found in those aged 18 to 35 (p=0.73).21 
It is likely that increased pregnancy loss in women 35 to 40 and older is due to 
greater numbers of oocyte chromosomal abnormalities in this age group. A study that 
retrospectively analyzed tissue samples from SABs found that 82% of samples from 
women aged 35 and over had abnormal karyotypes compared with 57% of samples from 
women under 35 (p<0.0005). Multivariate logistic regression analysis revealed maternal 
age to be predictive of first trimester loss due to aneuploidy (OR for each increasing year 
of maternal age 0.90 ± 0.003; p<0.001).22 Similarly, a retrospective cohort study 
examining the etiology of RPL in women over 35 found aneuploidy to be the cause of 
pregnancy loss in 70% of losses experienced by women without a history of RPL and in 
78% of losses in those with a history of RPL (three or more first trimester losses), 
revealing that women of advanced maternal age may experience high rates of pregnancy 
loss due to chromosomal abnormalities, regardless of obstetrical history.23 
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 2.3B Maternal Obstetrical History 
 Maternal obstetrical history is another factor influencing miscarriage risk. Studies 
have found that prior miscarriage negatively predicts subsequent pregnancy outcomes. 
One study found a four-fold increased risk of miscarriage in women with one or more 
previous miscarriages when compared to women with only successful pregnancy 
outcomes (OR 4.8; 95% CI, 2.5-9.4; p<0.0001).20 Lund et al. found that an increased 
number of prior miscarriages resulted in a statistically significant difference in chance of 
live birth among women in their study (p<0.01). Seventy-two percent of women with a 
history of three miscarriages gave birth to a child within a five year period, compared 
with 50% of women with six or more prior miscarriages (HR 0.55; 95% CI, 0.41-0.74).19 
A population-based case-controlled study found that miscarriage odds increased with 
each prior miscarriage. Using women with no prior miscarriage as a reference (OR 1.00), 
women with one prior miscarriage were found to have an OR of 1.65 for repeat 
miscarriage (95% CI, 1.47-2.31), 2.00 for two prior miscarriages (95% CI, 1.31-3.06), 
and 3.87 for three or more prior miscarriages (95% CI, 2.29-6.54). The study also found 
that a history of ever having had a live birth reduced the odds of miscarriage (OR 0.63; 
95% CI, 0.48-0.84). Miscarriage odds were not found to decrease with an increasing 
number of live births (p=0.71).21 Other studies have found, however, that a history of live 
birth may not have an impact on future pregnancy outcomes. Clifford et al. and Brigham 
et al. found similar pregnancy outcomes in those with primary and secondary RPL.3,24 
 2.3C Lifestyle Factors 
 Lifestyle factors such as tobacco use, alcohol use, caffeine intake, and maternal 
weight have been studied as factors influencing pregnancy outcomes. George et al. found 
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a two-fold increased risk of first trimester loss among smokers when compared with non-
smokers (adjusted OR 2.1; 95% CI, 1.1-4.1; p=0.02).20 Another study found a dose-
dependent relationship between tobacco and miscarriage, with miscarriage risk increasing 
with the number of cigarettes smoked per day.25 Conversely, some studies have found 
that smoking, even up to 20 cigarettes per day, does not increase the risk of SAB.21,26 
 Rasch et al. found an increased risk of SAB among women who drank five or 
more units of alcohol per week (OR 4.84; 95% CI, 2.87-8.16), but not in women who 
drank up to four units per week (OR 1.00; 95% CI, 0.74-1.34).26 Kesmodel et al. had 
similar findings, with an increased risk of first trimester SAB among women who 
consumed five or more drinks per week. Using less than one drink per week as a 
reference (HR 1.00), women drinking one to two drinks per week were found to have a 
HR of 1.3 (95% CI, 0.8-2.0), three to four drinks per week HR of 0.8 (95% CI, 0.4-1.7), 
and five or more drinks per week HR of 3.7 (95% CI, 2.0-6.8).27 
 Studies suggest that the impact of caffeine on risk of SAB is dose-related. Rasch 
et al. found that women who consumed 375 mg or more of caffeine per day were at a 
significantly increased risk of SAB (OR 4.84; 95% CI, 2.87-8.16) when compared with 
women who consumed 0-199 mg per day.26 In a prospective cohort study, Weng et al. 
found that increased daily doses of caffeine were associated with an increased risk of 
SAB. Compared with women who did not consume caffeine during pregnancy (HR 1.00), 
women who consumed less than 200 mg per day had a HR of 1.42 (95% CI, 0.93-2.15) 
for SAB and women who consumed more than 200 mg per day had a HR of 2.23 (95% 
CI, 1.34-3.69). This trend was found to be statistically significant (p<0.01).28 
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  The World Health Organization (WHO) designates Body Mass Index (BMI) 
categories as follows:  underweight: <18.50 kg/m2, normal: 18.50-24.99 kg/m2, 
overweight: ≥25.00 kg/m2, and obese: ≥30 kg/m2.29 A retrospective analysis investigating 
the impact of BMI on risk of miscarriage in subsequent pregnancies in women with RPL 
found that when compared to women with a normal BMI, underweight and obese women 
had higher odds of miscarriage (OR 3.98; 95% CI, 1.06-14.92 and OR 1.71; 95% CI, 
1.05-2.8). Overweight women were not found to have increased odds of miscarriage (OR 
1.02; 95% CI, 0.72-1.45).30 Helgstrand et al. found an increased risk of SAB in 
underweight women compared to women with a normal BMI (HR 1.24; 95% CI, 0.95-
1.63).31 Lashen et al. found obese women to be at a higher risk for both first trimester 
miscarriage (OR 1.2; 95% CI, 1.01-1.46) and RPL (OR 3.5; 95% CI, 1.03-12.01).32 
 2.3D Various Causes of RPL and Potential Treatments 
 A complete review of the various causes of RPL and their treatments is beyond 
the scope of this review. Some of the common causes will be discussed, however, as 
women with any cause for early RPL will be eligible for the study, and participants with 
known etiologies for RPL may present having received medical or surgical treatment. 
This discussion will introduce potential confounders and influence the sample size 
calculation. 
 It is estimated that 50% to 80% of early SABs are the result of chromosomal 
abnormalities, with variation due to maternal and gestational age at the time of loss.22 In 
women under 36, however, chromosomal abnormalities are more commonly the cause for 
pregnancy loss in sporadic SABs than they are in cases of RPL. A retrospective study 
examining the products of conception from 420 pregnancies found greater numbers of 
 28 
cytogenically abnormal specimens from women with sporadic losses when compared 
with specimens from women with a history of RPL. In women 18 to 29, 65% of 
specimens were chromosomally normal in women with RPL, compared with 52% in 
women with sporadic losses (p=0.03). Findings were similar for women 30 to 35, with 
63% of specimens being chromosomally normal in women with RPL, versus 48% in the 
control group (p=0.001). This difference was not found in women over 36.33 Another 
retrospective study analyzing the products of conception from 1,309 women with early 
RPL found that women with a greater number of prior SABs were more likely to have a 
chromosomally normal abortus than women with fewer prior losses (p=0.0063). Women 
with chromosomally normal products of conception were more likely to experience 
another SAB than women with a chromosomally abnormal abortus.34 
 Couples with RPL may undergo karyotyping to determine if either partner carries 
a chromosomal abnormality. Through analysis of 20,432 parental karyotypes from 
patients with RPL, Barber et al. found that two percent of the patients had chromosomal 
abnormalities, the most common being a balanced reciprocal translocation.35 A case-
controlled study comparing reproductive outcomes in couples with RPL found that 
couples with abnormal karyotypes had a greater chance of subsequent miscarriage when 
compared with couples with normal karyotypes. Forty-nine percent of couples with 
structural chromosomal abnormalities had subsequent miscarriages versus 30% of 
couples without abnormalities (95% CI, 11%-26%; p<0.01).36 A prospective cohort study 
of 51 couples with RPL and the presence of a structural chromosomal abnormality found 
a live birth rate of 71% in these couples with close evaluation and monitoring. Only 36% 
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of the miscarriages in the cohort had unbalanced structural chromosomal rearrangements. 
A high live birth rate was found without the utilization of reproductive technology.37 
 A systematic review found that congenital uterine anomalies are present in about 
6.7% (95% CI, 6.7-7.9) of the general population and 16.7% (95% CI, 14.8-18.6) of 
women with a history of RPL.38 Congenital uterine anomalies may predispose women to 
RPL by decreasing intraluminal volume and disrupting uterine blood supply. There are 
many types of congenital uterine anomalies, of which the septate uterus is the most 
common. Women with a septate uterus have a miscarriage rate of about 65%.39 These 
patients may undergo resection, reducing the risk of subsequent SAB. A systematic 
review found that in women who underwent septoplasty for a septate uterus, about 80% 
achieved term deliveries and only 15% experienced SAB.40 Roy et al. examined 
reproductive outcomes in women with a septate uterus and a history of RPL, infertility, or 
preterm delivery following hysteroscopic septum resection. A reduction in miscarriage 
rate from 91.5% prior to resection to 12.9% following resection (p=0.02) was observed.41 
 Uterine fibroids are another anatomic abnormality that may contribute to 
pregnancy loss. A systematic review examining pregnancy outcomes in women with 
fibroids who had undergone in-vitro fertilization found that women with fibroids had a 
SAB rate of 20.4% versus 12.9% in women without fibroids (OR 1.6; 95% CI, 1.3-2.0).42 
The association between fibroids and RPL is not entirely understood, but it is thought that 
large, submucosal fibroids may be associated with an increased risk of pregnancy loss. 
Treatment with myomectomy may improve pregnancy outcome in these patients.43,44 
 Antiphospholipid syndrome (APS) is an autoimmune condition characterized by 
the presence of antiphospholipid antibodies. Clinical manifestations, such as fetal loss, 
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are the result of vascular thrombosis and pro-inflammatory factors. APS is diagnosed as 
the cause of RPL in 15% of women, and these patients have a recurrent loss rate of about 
90% when not treated.45-47 A systematic review examining treatment efficacy in 
prevention of subsequent SAB in women with a history of pregnancy loss and APS found 
that treatment with heparin and aspirin may reduce pregnancy loss by 54%.48 Two trials 
found that combination therapy with aspirin and heparin significantly reduced the risk of 
SAB when compared to treatment with aspirin alone (RR 0.46; 95% CI, 0.29-0.71).49 
 Eight to twelve percent of pregnancy losses are the result of endocrine factors, 
such as thyroid dysfunction, polycystic ovarian syndrome, uncontrolled diabetes, and 
luteal phase deficiency.50 A systematic review found subclinical hypothyroidism to be 
associated with an increased risk of perinatal demise (OR 2.7; 95% CI, 1.6-4.7) when 
compared to euthyroid controls.51 A retrospective study found that with adequate 
treatment, 100% of patients with overt hypothyroidism achieved term deliveries. In 
contrast, a 60% SAB rate was found in inadequately treated women.52 The role of 
endocrine factors in RPL is not entirely understood, but women with well-controlled 
endocrine disorders generally have good pregnancy outcomes.50 
 In about 50% of couples with RPL, no definitive cause is identified and patients 
are diagnosed with idiopathic RPL.1,24,53,54 Patients with idiopathic RPL have high rates 
of success in subsequent pregnancies when treated with TLC alone.1-3,5 Women with 
idiopathic RPL may be offered pharmacological treatment, such as progesterone, aspirin, 
or heparin to improve pregnancy outcomes. A systematic review found a statistically 
significant reduction in SAB with the use of progesterone in women with idiopathic RPL 
compared to controls (OR 0.38; 95% CI, 0.20-0.70).55 Another systematic review, 
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examining the efficacy of anticoagulation in women with RPL to improve pregnancy 
outcomes, found insufficient data to recommend this treatment for women with idiopathic 
RPL56. A live birth rate of 81% was found in women receiving aspirin and a placebo 
control (RR 1.00; 95% CI, 0.78-1.29).56,57 Similar live birth rates were also observed in 
women receiving heparin (82%) and aspirin (84%) (RR 0.97; 95% CI, 0.81-1.16).56,58 
Due to inconclusive evidence regarding the efficacy of pharmacologic treatment in 
women with idiopathic RPL and the necessity of further trials, women with idiopathic 
RPL who are receiving empiric treatment will not be eligible for the proposed study. 
 Women with known causes for RPL and idiopathic RPL will be eligible for the 
proposed study. As substantiated by the data above, even treatment for a known cause of 
RPL does not result in a 100% success rate in subsequent pregnancies. Women will be 
identified at baseline as having a known cause for RPL or idiopathic RPL. 
2.4 Review of Relevant Methodology 
 This portion of the literature review will discuss relevant study design elements 
and methods to be utilized in the proposed study. The methodology of the proposed study 
will be fully discussed in Chapter 3. 
 2.4A Study Design 
 As described in Chapter 2.2A, the relationship between TLC and pregnancy 
outcomes in women with RPL has only been studied in the context of a quasi-
experimental prospective study and multiple prospective cohort studies.1-3,5 The proposed 
study will be a multicenter RCT examining the relationship between TLC and early 
pregnancy outcomes in women with a history of early RPL. This design will ensure that 
the groups are equivalent at baseline and will limit the potential for confounding and bias. 
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Several RCTs have been conducted in RPL patients to assess the efficacy of various 
treatments in preventing subsequent SAB and improving pregnancy outcomes.59-63 
 In order to limit selection bias, allocation to groups will be concealed in the 
proposed study. As in other multicenter RCTs utilizing women with RPL, randomization 
will be performed centrally by a computer program and communicated via phone.61-63 An 
independent coordinator will manage randomization, and the investigators at each site 
will be blinded to the randomization process.58 Patients will be stratified by known versus 
unknown etiology for RPL, enabling subgroup analysis of pregnancy outcomes between 
the two groups. In a RCT conducted by Laskin et al., RPL patients were stratified 
according to the presence or absence of antiphospholipid antibodies for this purpose.62 
 2.4B Patient Selection 
 In many studies involving women with RPL, including each of the TLC studies 
described in Chapter 2.2A, women are recruited for study participation from RPL clinics 
or specialized reproductive departments in hospitals.1-3,5,53,58,64,65 The proposed study will 
take place at reproductive and infertility specialty centers, and eligible women attending 
these centers will be will be notified of the study and recruited for participation. 
Women with a history of early RPL – two or more consecutive clinical pregnancy 
losses during the first trimester – will be eligible for the proposed study.24,53,60-63,65-68 
Although some studies define RPL as three or more losses, two or more losses will be 
used in the proposed study because the prevalence and frequency of RPL etiology does 
not significantly differ in women with two versus three losses.53,62 In women with a prior 
live birth, the two most recent pregnancies must have ended in pregnancy loss in order to 
be eligible for participation.60 The four prior TLC studies only included women with 
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idiopathic RPL.1-3,5 The proposed study, however, will include women with known and 
unknown etiologies for RPL. As discussed in Chapter 2.3A, maternal age is a potential 
confounder to the association between TLC and early pregnancy outcome. Women 
between the ages of 18 and 39 will be eligible for the proposed study.3,19-22 
Exclusion criteria will include history of psychiatric illness, presence of 
uncontrolled chronic disease or endocrine disorder, and history of thrombophilia or 
venous thromboembolism.56,59,69 To limit confounding, women will be asked to abstain 
from tobacco and alcohol and consume no more than 200 mg of caffeine per day.20,26-28 
Women with BMIs <18.50 kg/m2 and ≥30 kg/m2 will not be eligible for the study.30-32 
Women eligible for the study will be enrolled and consented prior to becoming 
pregnant, but will not be randomized until a pregnancy is established.62 It is expected that 
about 85% of the women enrolled for the proposed study will become pregnant during 
the study period.1,2,24,53 Therefore, the number of women enrolled for the study will be 
15% greater than the calculated number of women needed for randomization.61 
 2.4C Intervention 
 The components of TLC included in each of the prior TLC studies are fully 
described in Chapter 2.2A. TLC differed in each of the studies, but there are important 
similarities.1-3,5 In each of the studies, TLC included some form of a weekly medical visit 
and physical exam. Specifically, in the studies by Liddell et al., Clifford et al., and Al-
Otaibi et al., TLC included weekly first trimester ultrasounds beginning at four to five 
weeks.2,3,5 Weekly ultrasounds have also been included as a component of patient 
management in other studies including women with RPL.24,53 A qualitative study by 
Musters et al. examined the preferences of patients with RPL and found that women 
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strongly desire weekly or bi-weekly ultrasounds once the pregnancy can be seen on 
ultrasound.70,71 Women in the TLC group in the proposed study will receive weekly 
transvaginal ultrasounds from five to twelve weeks of gestation.24 They will be 
encouraged to visualize their developing pregnancy on the screen.2 Women also prefer 
frequent serum hCG monitoring until the pregnancy can be visualized on 
ultrasound.2,5,63,70,71 The appropriately rising hCG provides women with reassurance.70,71 
Serum hCG will be measured every two days until a value of 2,000 mIU/mL is reached 
or surpassed in women receiving TLC in the proposed study. 
 Women with RPL prefer that their care during the first trimester be well defined 
and planned from the beginning of the pregnancy.71 Continuity of care from the same 
medical staff at each visit is a key component of TLC.2,3 Women with RPL prefer 
continuity of care because they want their providers to know them well. Women desire 
their physicians to exhibit empathy and support, listen to their concerns, and address their 
emotional needs.65,70,71 In addition, women prefer that their partners attend prenatal visits 
with them and be directly involved in the care of the pregnancy.65,71 
The psychological and emotional needs of RPL patients are addressed in a variety 
of ways in the previous TLC studies. In the studies by Liddell et al. and Al-Otaibi et al., 
TLC included frequent reassurance and feedback on the status of the pregnancy, as well 
as time during each visit to address questions and concerns and elicit advice appropriate 
to the gestational age of the pregnancy.3,5 Women prefer this as an element of their TLC 
care, as well as the availability of a social worker for counseling purposes.71 Finally, RPL 
patients desire to be seen by their providers and receive ultrasounds in the case of 
 35 
symptoms of miscarriage.71 All of the above components will be included in the TLC 
provided to patients in the intervention group in the proposed study. 
 The studies by Stray-Pederson et al., Clifford et al., and Musters et al. included 
formal stress reduction and relaxation techniques as a component of TLC.1,3,71 This will 
not be included in the proposed study, as women will have the availability of a social 
worker. TLC in the study by Stray-Pederson et al. included bed rest during the gestational 
period at which prior losses had occurred.1 However, Musters et al. found that women do 
not prefer this treatment.71 Stray-Pederson et al. also advised women in their TLC group 
to avoid heavy work, traveling, and sexual intercourse.1 However, the evidence regarding 
the avoidance of intercourse and bed rest during pregnancy to prevent SAB is lacking.72,73 
Women in the proposed study will not be advised to abstain from sex or to take bed rest.  
 2.4D Comparison 
 In the TLC studies by Stray-Pederson et al. and Liddell et al., the women who did 
not receive TLC were told to attend their local antenatal clinic or their standard OB-GYN 
for prenatal care.1,2 In the proposed study, women randomized to the control group upon 
becoming pregnant will be released to the care of their standard OB-GYN to receive 
routine prenatal care, which is typically initiated between eight to ten weeks of gestation.  
 2.4E  Monitoring of Adverse Events 
 Bleeding is a common event in the first trimester. A study assessing pregnancy 
outcomes in patients with first trimester bleeding found that those with light and heavy 
bleeding were more likely to a have a SAB before 24 weeks than those without bleeding 
(OR 2.5; 95% CI, 1.5-4.3 and OR 4.2; 95% CI, 1.6-10.9 respectively).74 Not all bleeding 
during pregnancy is the result of impending miscarriage, however. First trimester 
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bleeding may be the result of cervical lesions, ectopic pregnancy, SAB, or vaginitis.75 In 
the TLC study by Liddel et al., 40% of the patients who had successful pregnancies 
experienced bleeding in the first trimester.2 In the proposed study, women will be told to 
notify their healthcare provider in the case of bleeding. 
 In the case of ectopic pregnancies, diagnosed by the absence of an appropriately 
rising serum hCG prior to the establishment of clinical pregnancy by ultrasound or the 
absence of an intrauterine pregnancy on ultrasound, TLC patients will be managed by 
their TLC clinicians and those in the control group will be managed by their standard 
OB-GYN provider.2,3,76 Subsequent SABs will be managed in this way as well.1-3,5,61,63,76 
Studies involving pregnant women with a history of RPL often mention termination of 
pregnancy due to fetal anomalies.3,24,58,76 In the proposed study, couples who choose to 
terminate a pregnancy will be referred to clinicians who can manage the termination. 
2.4F Primary Outcome Measures 
The TLC study by Al-Otaibi et al. assessed pregnancy outcome at 12 weeks of 
gestation as the primary outcome measure in their participants.5 The primary outcome 
measure in the proposed study will be the presence of an ongoing viable pregnancy 
(viewed on transvaginal ultrasound) at twelve weeks of gestation.24 Many studies 
involving RPL patients utilize live birth as the primary outcome (or assess the primary 
outcome at the completion of pregnancy).1-3,58,60-62 Pregnancy outcome at 12 weeks is a 
reasonable outcome, however, as most pregnancy losses in prior studies occurred during 
the first trimester.2,3,24,53 Women in the proposed study will have a history of early RPL 
and it is likely that they will continue to have first trimesters losses if they have a 
subsequent SAB. In addition, many studies utilizing TLC or increased supportive care for 
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women with RPL discontinue this care at the end of the first trimester of pregnancy, 
suggesting that this is the most critical period in the pregnancy for risk of SAB.2,3,24,53,60,62 
 2.4G Secondary Outcome Measures 
 Secondary outcome measures will include the occurrence of adverse events (see 
Chapter 2.4E). Psychological distress will also be measured as a secondary outcome in 
order to assess the impact that TLC may exert on levels of psychological distress in 
women with RPL. Many screening tools are available for measuring psychological 
symptoms in patients, some of which are mentioned in Chapter 2.2B. 
The Edinburgh Depression Scale will be utilized in the proposed study for the 
assessment of psychological distress.14,77,78 The Edinburgh Postnatal Depression Scale 
(EPDS) was originally developed as a self-report screening scale for postnatal depression. 
The 10-item scale takes five minutes to complete and is acceptable to patients and easy to 
score. The 10 items are scored on a four-point scale (a score of zero to three for each item 
and a total score of zero to thirty), with higher scores indicating greater levels of 
depressive symptoms. Women are asked to complete the EPDS based on their feelings in 
the past week. Using 12 as a threshold for identifying depression, the EPDS was found to 
have a sensitivity of 86%, a specificity of 78%, and a positive predictive value of 73%.14 
Although originally validated in postpartum women, the EPDS has since been 
validated in pregnant women. Using 12 as a threshold for identifying women with 
depression, the scale was found to have a sensitivity of 64%, a specificity of 90%, and a 
positive predictive value of 50%.14 When the EPDS is not utilized in the postpartum 
period, the scale is called the Edinburgh Depression Scale (EDS).77 
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Although other scales, such as the General Health Questionnaire,17 the State-Trait 
Anxiety Inventory,9 and the Hospital Anxiety and Depression Scale,79 have been 
validated for use in pregnant women, the EDS was created specifically for pregnant 
women and is well-tolerated.80 In addition, the EDS does not only screen for depression, 
as studies have shown that the EPDS/EDS contains an anxiety subscale and women with 
various psychiatric disorders are captured at a threshold score of 12.81-84 Therefore, it is 
appropriate to use the EDS as a measure of psychological distress in pregnant women 
with RPL. The EDS also has good test-retest reliability and validity.85-87 
It is recommended that women who score 12 and higher on the EPDS/EDS be 
referred for psychiatric evaluation.14 Therefore, women scoring 12 or higher on the EDS 
in the proposed study will be advised to notify their general practitioner or OB-GYN 
clinician of their score on the EDS at the end of the study. 
 2.4H Other Variables 
 Information to be collected at baseline will include age at randomization, 
ethnicity, marital status, BMI (underweight or overweight), known vs. unknown etiology 
for RPL, primary vs. secondary RPL, and number of previous losses. The rationale for 
collecting these variables is outlined in Chapter 2.3. Age will be assessed as an ordinal 
variable. Categories will be 18-24, 25-29, 30-34, and 35-39 years old.3,19-21 Primary vs. 
secondary RPL will be collected as a nominal variable. Women with no prior history of a 
live birth will be identified as primary RPL patients and women with a history of prior 
live birth before the occurrence of two or more consecutive early losses will be identified 
as secondary RPL patients.24,58 The number of previous losses will be collected as an 
ordinal variable with the categories being two, three, four, five, and six or more losses.3,53 
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 2.4I Sample Size and Statistical Significance 
 Due to the small number of studies similar to the proposed study, the elements 
utilized to calculate an appropriate sample size to sufficiently power the study and find a 
statistically significant result will be based upon estimates from previous studies 
including women with RPL. A study by Habayeb et al. examining the efficacy of a RPL 
clinic and its impact on pregnancy outcomes found live birth rates of 75% in those with 
idiopathic RPL, 64% in those with thrombophilias, 83% in those with autoimmune 
antibodies, 71% in those with polycystic ovarian syndrome, and 57% in those with 
abnormal karyotypes. The average live birth rate for women with these diagnoses was 
70%. The results of this study are helpful in estimating the expected pregnancy outcome 
in the comparison group in the proposed study because the study included women with 
known causes for RPL and idiopathic RPL, and the women may have received diagnosis-
specific treatment. Although they did receive frequent ultrasounds, the women did not 
receive specialized and well-defined supportive care.53 A successful pregnancy outcome 
of 70% will be expected in the comparison group in the proposed study. Rates of 
successful pregnancy outcomes were much lower in the TLC studies described in Chapter 
2.2A because they included only women with idiopathic, untreated RPL.1-3 A successful 
pregnancy outcome of 85% will be expected in the TLC group in the proposed study. 
This is based on the average successful pregnancy outcome found in the TLC groups in 
prior TLC studies.1-3  Although these studies only included women with untreated, 
idiopathic RPL, these are the best numbers available to estimate the expected successful 
pregnancy outcome for the proposed study. A 15% difference in successful pregnancy 
outcome will be expected and considered statistically significant in the proposed study. 
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The proposed study will utilize a power of 80% and a significance level of 5% in 
order to sufficiently power the study and calculate an appropriate sample size. The study 
will account for an expected 10% dropout rate by increasing the sample size by 10%.62 
2.4J Statistical Analysis Considerations 
 The proposed study will examine early pregnancy outcome in women with RPL 
who become pregnant during the study period. Analysis will include only those women 
who become pregnant during the study and are randomized for treatment, not all women 
who are enrolled and consent for study participation.60,63 
 An intention-to-treat analysis will be utilized in the proposed study, including 
patients lost to follow-up, ectopic and molar pregnancies, terminations, and losses prior 
to the establishment of clinical pregnancy (biochemical losses).58,62 In a RCT by 
Stephenson et al., pregnancy outcomes were analyzed only among those who achieved 
clinical pregnancy, excluding biochemical losses.63 In the proposed study, a sub-group 
analysis will look at the pregnancy outcomes at 12 weeks of gestation in women who 
achieve a clinical pregnancy, as recognized by ultrasound at five weeks of gestation. 
2.5 Conclusion 
 While studies have shown that providing women with a history of RPL with TLC 
during subsequent pregnancies may improve pregnancy outcome, a sufficiently powered 
and well-designed RCT with an appropriate sample size is necessary to determine the 
impact of TLC on pregnancy outcome. A RCT is also necessary to determine the impact 
that TLC may have on levels of psychological distress in women with RPL. The 
information above provides the rationale for the study design and methods that will be 
further outlined in Chapter 3.  
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 CHAPTER 3:  STUDY METHODS 
3.1 Study Design 
 The proposed study will be a multicenter randomized controlled trial to assess the 
difference in rates of successful pregnancy outcome at 12 weeks of gestation in women 
with a history of early RPL who receive TLC during the first trimester of pregnancy 
when compared with women who receive standard prenatal care during the first trimester. 
3.2 Study Setting 
 The proposed study will take place at five reproductive endocrinology and 
infertility specialty centers in CT, MA, and NY. The selected institutions are within the 
Society for Assisted Reproductive Technologies (SART) network. See Appendix A for 
institution list. 
3.3 Study Population and Sample Size 
 The source population for the proposed study is women with a history of early 
RPL, defined as two or more consecutive clinical pregnancy losses during the first 
trimester. The study population will be selected via convenience sampling of women 
receiving care at selected institutions within the SART network (Appendix A). 
 Women aged 18 to 39 with a history of two or more consecutive first trimester 
clinical pregnancy losses (pregnancy confirmed by ultrasound or histopathologic 
evaluation) will be eligible for enrollment in the proposed study. In women with a history 
of prior live birth, the two most recent pregnancies must have ended in pregnancy loss. 
Women with both explained and unexplained RPL will be eligible for the participation 
(women must present already having undergone a workup for RPL). Women with a 
known cause for RPL may receive specific treatment prior to their enrollment in the 
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study. Women with an unknown etiology for RPL will not be eligible for the proposed 
study if they receive additional treatment prior to or during their enrollment in the study. 
Exclusion criteria for the proposed study will include the following:  history of 
psychiatric illness, uncontrolled chronic disease (neurologic, cardiac, pulmonary, renal 
and gastroenterology conditions), uncontrolled endocrine disorders (diabetes and hypo-
/hyperthyroidism), history of thrombophilia or venous thromboembolism, BMI <18.50 
kg/m2 or ≥30 kg/m2, conception by in-vitro fertilization or artificial insemination, and 
participation in another clinical study during the study period. In order to participate in 
the study, women must agree to abstain from tobacco and alcohol and consume no more 
than 200 mg of caffeine per day during the period of time during which they are enrolled. 
Women will be consented for participation in the proposed study once they have 
been screened for eligibility and meet the above criteria. Women will be eligible for 
randomization to treatment groups upon the establishment of pregnancy. Patients will 
only be eligible for study participation during one pregnancy. 
3.4 Subject Protection and Confidentiality 
 The Human Investigation Committee (HIC) at Yale University and an equivalent 
committee at the other sites must approve the study protocol prior to the initiation of the 
study. Applications for research using human subjects must be completed, submitted, and 
approved at each institution. All eligible patients must give written informed consent 
prior to their study participation. The informed consent form will be formatted to meet 
the requirements of each institution (see Appendix B for the form to be used at Yale). 
 The study protocol will be in compliance with current Health Insurance 
Portability and Accountability Act (HIPAA) regulations and all personnel involved in the 
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study will complete HIPAA training prior to the study’s initiation. Patient confidentiality 
will be protected by the assignment of a unique identification number to each participant. 
Forms utilized to collect patient information will be labeled with the patient IDs and these 
numbers will be used for data entry and analysis. Patient records will be stored in locked 
cabinets at each institution when not in use and electronic patient information will be 
stored on encrypted and password-protected computers. 
3.5 Recruitment 
 Prior to the start of the study, a letter describing the study and outlining the 
eligibility requirements will be distributed to the staff at each participating institution 
(Appendix C). Informational meetings will also be held at each institution. Medical staff 
will be asked to refer women that meet the inclusion and exclusion criteria for the study. 
Rolling basis recruitment will take place between January 1, 2015 and August 1, 2016. 
 The institution principle investigator (PI) will approach women who meet the 
eligibility criteria to discuss the purpose and methods of the study. Potential risks and 
benefits will be disclosed. Women uncertain about or not interested in study participation 
will be given a flyer to take home and asked to contact the institution PI if they have 
questions (Appendix D). Women interested in participation will be required to give 
written informed consent (Appendix B). The institution PI will read the form to the 
patient and answer any questions. The patient will then read the form herself. The patient 
and institution PI will both sign and date the consent form. 
 Following consent, a clinician will collect baseline characteristics (see Appendix 
E for form) and perform a physical exam. If the patient remains eligible for study 
participation, she will be asked to contact the institution upon becoming pregnant. 
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We expect that not all women enrolled for the study will become pregnant during 
the study period and a pregnancy rate of 85% is estimated. The proposed study will aim 
to enroll at least 308 women, anticipating that 85% (267) will become pregnant and 
randomized for treatment. The sample size calculation will be discussed in Chapter 3.13. 
Between 2005 and 2010, about 450 women with RPL presented to Yale Fertility 
Center – an average of about 90 women each year. Recruitment for the proposed study 
will take place at five institutions over 19 months. Using the data from Yale as a guide, it 
is reasonable to estimate that more than 308 women with RPL will present to the selected 
institutions and be eligible for study enrollment during the recruitment period. 
3.6 Assignment of Treatment Groups 
Upon becoming pregnant, women will present to their respective institution for 
confirmation of pregnancy by serum hCG and then randomized to study groups. 
Randomization will be performed centrally by a computer program and communicated 
via phone. Institution PIs will contact an independent randomization coordinator and 
supply patients’ IDs. Patients will be stratified by known versus unknown etiology for 
RPL and randomly assigned to receive TLC or standard prenatal care. Group assignments 
will be communicated to the institution PIs, who will contact participants. The 
randomization coordinator will not be involved in the enrollment or intervention phases 
and the institution PIs will be blinded to the randomization process. A database of patient 
IDs and group assignments will be stored on an encrypted computer at the central facility. 
3.7 Intervention 
 Women randomized to the intervention group will receive TLC during the first 
trimester of pregnancy (until 12 weeks of gestation). At the first TLC visit, the 
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components of TLC will be reviewed with each patient. The timeline of visits to the 
clinic will be outlined and the women will be informed of what to expect during their 
clinic visits. Women will receive a form at this visit, outlining her visits to the clinic 
during the first trimester of pregnancy. A medical assistant (MA) and the scheduling staff 
at each office will complete this form. See Appendix F for a copy of the form. 
After a positive pregnancy test, women will present to the clinic every two days 
for serial hCG measurements to ensure that the hCG is rising appropriately. After 
reaching a hCG threshold of at least 2,000 mIU/ml, patients will receive weekly 
transvaginal ultrasounds from approximately five weeks of gestation until twelve weeks 
of gestation. Women will be encouraged to visualize their developing pregnancy on the 
monitor and the provider will point out visible structures. 
Women will be given feedback regarding the progression of the pregnancy and 
reassurance if everything is progressing appropriately at each visit. They will also be 
given time to ask questions and elicit advice applicable to the gestational age of the 
pregnancy. Patients will be encouraged to bring their partner with them to visits. Partners 
will be engaged during the visits through encouragement to visualize the pregnancy on 
the ultrasound screen, involvement in conversations, and encouragement to ask questions. 
 Women in the TLC group will be seen by the same healthcare staff (medical 
assistant and MD or PA) at each clinic visit. This continuity of care will promote the 
formation of a trusting relationship between the patient and her healthcare providers and 
help the patient feel as though the staff knows her. The goal of this continuity of care will 
be to help women feel more comfortable attending the clinic during the first trimester. 
Providers managing patients in the TLC group will be advised to exhibit empathy and 
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support when engaging with the women. They will be asked to address the emotional 
needs of the patients and listen to concerns that arise. A social worker will be available at 
the clinic if women feel as though they need to speak to someone further regarding their 
psychological and emotional well-being. The social workers will be available to provide 
counseling and support services if patients desire to utilize this component of TLC. 
Women will be reminded of this resource at each visit. 
 Women in the TLC group will be advised to notify the clinic if they have 
concerns or experience bleeding during the first trimester. Women will be able to speak 
to their healthcare provider or come in for a visit if they so desire. 
 Women in the intervention group will also be asked to establish a relationship 
with their standard OB-GYN practitioner. They will be advised to notify their practitioner 
upon becoming pregnant and asked to follow their prenatal care instructions and 
appointment schedule. This will ensure that women in the TLC group receive standard 
prenatal care and aid in the continuity of care at the completion of the study intervention. 
3.8 Comparison 
 Women randomized to the comparison group will be asked to attend the clinic of 
their standard OB-GYN practitioner for routine prenatal care. Women will be told to 
notify their OB-GYN upon becoming pregnant and asked to follow their prenatal care 
instructions and appointment schedule. They will be advised to notify their OB-GYN 
provider if they have any concerns regarding their pregnancy during the study period. 
3.9 Adherence 
 Adherence to treatment in the intervention group will be monitored by recording 
the participants’ TLC office visits (Appendix G). If a patient misses an appointment, she 
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will be contacted by phone and the visit will be rescheduled accordingly. Adherence to 
treatment in the comparison group will be difficult, as patients will be released to the care 
of their standard OB-GYN. Women in the comparison group will be asked to give a self-
report of their prenatal care at the completion of the study. 
3.10 Study Variables and Measures 
 The following patient baseline characteristics will be collected and recorded on 
the form found in Appendix E:  age category at randomization (18-24, 25-29, 30-34, or 
35-39 years old), ethnicity (Hispanic or Latino, American Indian or Alaska Native, Asian, 
Black or African American, Native Hawaiian or Other Pacific Islander, or White), marital 
status (married or not married), BMI category (normal weight: 18.50-24.99 kg/m2 or 
overweight: 25.00-29.99 kg/m2), known or unknown etiology for RPL, primary (no 
history of prior live birth) or secondary (history of prior live birth) RPL, and numerical 
category of previous losses (two, three, four, five, or six or more). 
 Pregnancy will be confirmed prior to randomization for treatment through the 
measurement of serum hCG. Women in both groups will be assessed for the presence of a 
clinical pregnancy, as visualized on transvaginal ultrasound, at five weeks of gestation. 
The primary outcome measure will be the presence of an ongoing viable pregnancy at 12 
weeks of gestation, as visualized by transvaginal ultrasound. 
 Secondary outcome measures will include first trimester bleeding, ectopic and 
molar pregnancies, subsequent SAB, and the termination of pregnancy. In addition, 
psychological distress will be a secondary outcome measure. The Edinburgh Depression 
Scale (EDS) will be utilized to measure psychological distress (Appendix H). Women in 
both groups will complete the EDS when they present to the office for serum hCG 
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confirmation of pregnancy and when they present for assessment of clinical pregnancy 
status at 12 weeks. 
3.11 Data Collection 
 Eligible women will undergo a history and physical exam following consent for 
study participation. Baseline characteristics will be collected at this time (Appendix E). 
Each patient will have a data collection form to be kept under lock and key at her 
respective site (Appendix I). The form will include the patient’s ID, date of last menstrual 
period (for the calculation of gestational age), initial hCG, documentation of clinical 
pregnancy at five weeks of gestation, pregnancy outcome at 12 weeks, EDS scores, 
presence/absence of a multiple gestation pregnancy (pre- and post-intervention), adverse 
events, and establishment of routine prenatal care. 
Study participants will be asked to notify their respective institution upon 
becoming pregnant. At this time they will present for the measurement of serum hCG by 
a medical assistant (MA). All women randomized to a study group will present for 
confirmation of clinical pregnancy at five weeks of gestation by transvaginal ultrasound. 
They will return at 12 weeks of gestation for the assessment of clinical pregnancy status. 
A clinician blinded to group assignment will perform these ultrasounds. Study 
participants will complete the EDS when they present for confirmation of pregnancy by 
hCG and when they present for assessment of clinical pregnancy at 12 weeks. A clinician 
blinded to group assignment will score the EDS (scoring scale found in Appendix H). 
Another form will be utilized for women in the TLC group (Appendix G) to keep 
track of hCG and ultrasound monitoring visits, the patients’ utilization of resources, and 
additional visits or phone calls that patients make to their respective institution. 
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3.12 Monitoring of Adverse Events 
 Monitoring of adverse events will include first trimester bleeding, ectopic and 
molar pregnancies, subsequent SAB, and termination of pregnancy. Women will be asked 
to notify their healthcare providers if they experience first trimester bleeding. Women in 
the TLC group will contact their clinician at the study institution, and women in the 
comparison group will contact their standard OB-GYN. Ectopic pregnancies will be 
diagnosed by the absence of an appropriately rising serum hCG prior to the establishment 
of clinical pregnancy and the absence of an intrauterine pregnancy on ultrasound. 
Clinicians at the study institutions will manage molar and ectopic pregnancies and 
subsequent SABs in women assigned to the TLC group. Women in the routine prenatal 
care group will be managed by their OB-GYN clinicians. If a fetal anomaly is identified 
in patients in either group, and the couple desires to terminate the pregnancy, they will be 
referred to clinicians who can aid in management of the termination. 
 The EDS will be used to measure psychological distress. Women who score 12 or 
higher will be advised to notify their general practitioner or OB-GYN of their EDS score 
at the end of the study. The EDS is a screening tool and cannot be used for diagnosis. 
Patients scoring 12 and higher should undergo a clinical psychiatric evaluation. 
3.13 Sample Size Calculation 
 We estimated that a sample size of 242 total patients, with 121 patients in each 
group, will be needed to test a two-sided hypothesis with a five percent confidence level 
and 80% power. A two-sample proportion calculation (Chi-square test) was utilized for 
the determination of the sample size via Version 4 of Power and Precision software. 
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Using data from prior studies, we estimated rates of successful pregnancy 
outcome (ongoing viable pregnancy at 12 weeks of gestation, as visualized by 
ultrasound) of 70% in the standard prenatal care group and 85% in the TLC group. The 
observation of an absolute 15% difference (effect size) in the rate of successful 
pregnancy outcome between the two groups requires a sample size of 121 patients per 
group (242 patients total). An estimated 10% loss to follow-up rate is expected and will 
be accommodated for by randomizing 267 patients for treatment in the study.  
3.14 Statistical Analysis 
 The most recent edition of Statistical Analysis System software will be utilized 
for statistical analysis. The statistician will be blinded to group assignment. Probability 
values less than 0.05 will indicate statistical significance. 
 Baseline patient characteristics will be collected and compared between the two 
groups using descriptive statistics. Categorical variables (age category at randomization, 
ethnicity, and numerical category of previous pregnancy losses) and dichotomous 
variables (marital status, BMI category, known versus unknown etiology for RPL, and 
primary versus secondary RPL) will be compared between the groups by Chi-square 
tests. 
 The unadjusted association between TLC and successful pregnancy outcome at 12 
weeks of gestation will be compared between the groups using the Chi-square test. 
Multivariate analysis will be performed using logistic regression, taking into account 
covariates. Covariates selected for multivariate analysis will be age category at 
randomization, numerical category of previous pregnancy losses, known vs. unknown 
etiology for RPL, and primary vs. secondary RPL. The primary outcome analysis will be 
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performed on an intention-to-treat basis. A sub-group analysis of women who achieve a 
clinical pregnancy will also be conducted to compare the association between TLC and 
successful pregnancy outcome between the intervention and comparison groups. This 
sub-group analysis will also exclude ectopic and molar pregnancies, terminations, and 
multiple gestation pregnancies. 
 A stratified analysis will be conducted to compare the association between TLC 
and successful pregnancy outcome at 12 weeks among women with a known etiology for 
RPL and women with an unknown etiology for RPL using an interaction term. 
 Comparison of secondary outcome measures of dichotomous variables 
operationalized by frequency, including first trimester bleeding, ectopic and molar 
pregnancies, SAB, and termination of pregnancy, will be performed by Chi-square tests. 
The association between TLC and psychological distress will be measured using 
the EDS at baseline and post-intervention. The EDS will be scored using the scoring 
scale found in Appendix H. The difference between the baseline and post-intervention 
scores will be calculated (change score) and the difference in mean change scores 
between the two groups will be evaluated using the student’s t-test. Multivariate analysis 
will be performed using linear regression. 
3.15 Timeline and Resources 
 Rolling basis recruitment will take place from January 1, 2015 to August 1, 2016. 
Women will be able to notify their institution of a pregnancy until September 1, 2016. 
This will ensure that all data collection can take place by mid-December, 2016. Data 
collection will end on December 31, 2016. The duration of the intervention will be from 
randomization following the confirmation of pregnancy by serum hCG through 
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pregnancy loss or assessment of pregnancy at 12 weeks of gestation by transvaginal 
ultrasound. Statistical analysis will take place after the completion of data collection. 
 Study personnel will include the study PI, Pinar Kodaman, MD, and co-PI, Emily 
Gruetzmacher, PA-SII. An institution PI will be assigned to each site. They will be 
responsible for recruiting and consenting eligible women for study participation. They 
will also communicate the randomization of study participants at each site and manage 
patient documentation and data forms. The institution PIs will be blinded to the 
randomization process. MAs and clinicians (MDs and PAs) working at each of the five 
institutions will be asked to participate in the study. Those who agree to participate will 
be identified and assigned patients upon patient randomization. The MAs will be 
responsible for all phlebotomy. Clinicians who agree to participate in providing patients 
with TLC will be asked to exhibit empathy and support to their patients, listen to 
questions and concerns, and address emotional needs. Clinicians not involved in the 
provision of TLC at each site will be needed to assess clinical pregnancy at five and 
twelve weeks of gestation and score the EDS at the beginning and end of patients’ study 
participation. These clinicians will be blinded to group assignments. A social worker will 
be needed at each site. In addition, the study will require an independent randomization 
coordinator and a statistician for data analysis. These individuals will not be involved in 
the recruitment or intervention phases of the study. 
 The study PI and co-PI will work from Yale School of Medicine. A workstation 
with a desk and a computer will be needed at each institution for the institution PI. 
Resources at each institution, such as exam rooms and ultrasound machines, will be 
utilized. Blood samples will be sent to and analyzed at labs associated each institution. 
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CHAPTER 4:  CONCLUSION 
4.1 Study Advantages 
The proposed study will be a RCT examining the relationship between TLC and 
early pregnancy outcomes and levels of psychological distress in women with a history of 
early RPL. The study design is an important advantage of the study because it will 
minimize selection bias and the potential for confounding by ensuring that the two groups 
are equal with respect to baseline characteristics. Allocation concealment and utilization 
of a central randomization process will also aid in reducing selection bias. 
Another strength of the study is adherence to a power of 80% and a significance 
level of 5% to generate statistically significant results. The sample size necessary for the 
study is achievable, considering the number of RPL patients that presented to Yale over a 
five-year period and the utilization of five institutions. It is reasonable to presume that a 
sufficient number of patients will present for enrollment during the recruitment period. 
Women will only be eligible for study participation for one pregnancy. This is 
advantageous because the inclusion of more than one outcome from the same patient may 
skew the data, as pregnancy outcomes are often linked to maternal variables (such as age 
and number of previous losses).1 The proposed study will include women with both 
known causes for RPL and idiopathic RPL. The inclusion of both groups of women will 
give the study good external validity and make the results more generalizable to all 
women with a history of RPL. Finally, the utilization of two or more consecutive first 
trimester pregnancy losses as the definition for early RPL is important.2,3 This will aid in 
the recruitment of enough eligible participants. It is also advantageous because the 
diagnosis of an etiology for RPL does not differ in women with two versus three losses.4 
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4.2 Study Disadvantages and Limitations 
One of the main limitations of the proposed study is the difficulty of standardizing 
some aspects of the methods. Women in the comparison group will be released to their 
standard OB-GYN clinician for prenatal care. They will be seen by different clinicians 
and will receive variations of prenatal care. Clinicians vary in their interactions with 
patients and in their willingness to see patients for additional visits as concerns arise. In 
addition, clinicians providing TLC will be asked to exhibit empathy and support, listen to 
questions and concerns, and address the emotional needs of the patients. These qualities 
will naturally vary from clinician to clinician. Women in the intervention group will also 
have some control over the amount of care they receive. They will have the option of 
seeing a social worker at each visit and the availability of phone calls and office visits if 
concerns arise. This will cause variation in the amount of care that women receive. 
Another disadvantage of the study is the potential costliness of TLC. The 
intervention will necessitate considerable planning and require staff trained in the 
management of RPL patients and the use ultrasound equipment. The intervention will 
require the availability of time for TLC appointments and office space.5 The dropout rate 
may be high in the intervention group due to the frequency at which patients must present 
for TLC. It is difficult to anticipate this, however, and it is likely that the patients will be 
highly motivated, as they will be recruited from reproductive clinics. This introduces 
another disadvantage:  patients that present for care at these clinics may be homogeneous 
in terms of demographics and socioeconomic status, potentially limiting the study’s 
external validity.6 The feasibility of providing TLC to RPL patients in standard OB-GYN 
clinics will not be assessed and it may be difficult to replicate TLC in this setting. 
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The assessment of pregnancy outcome at 12 weeks of gestation, as opposed to the 
conclusion of pregnancy, may be viewed as a disadvantage of the study. The presence of 
an ongoing viable pregnancy at 12 weeks is a reasonable outcome measure, however, 
because most pregnancy losses occur during the first trimester. Patients with first 
trimester pregnancy loss will continue to lose during the first trimester.7-10 
Finally, the study may be influenced by recall bias. Women will be asked to 
report their number of previous losses and their experience of at least two clinically 
recognized first trimester losses. It may not be possible to verify this information.1 
4.3 Clinical Significance 
Pregnancy loss is the most common adverse event of pregnancy and one to five 
percent of women experience RPL.11-13 The psychological implications of SAB and RPL 
can be severe, with symptoms of anxiety and depression sometimes continuing even after 
the birth of a healthy child.14 Psychological distress during pregnancy can negatively 
affect pregnancy outcomes and contribute to significant morbidity in offspring.15-17 
The proposed study will aid in determining if TLC does in fact influence 
pregnancy outcomes in women with RPL. The study will also assess the impact of TLC 
on levels of psychological distress in these patients. This information will provide the 
evidence and rationale for providing women with a history of two or more consecutive 
pregnancy losses with TLC. The study will also provide clinicians with a definition for 
TLC that outlines the components of care that are most effective and preferred by 
patients. A better understanding of the components of TLC and the relationship between 
TLC and pregnancy outcomes and psychological distress in women with RPL will guide 
clinical decision-making and patient management. 
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Appendix A:  Institution List 
 
The proposed study will take place at the following institutions, all of which are 
associated with the Society for Assisted Reproductive Technology (SART). 
 
CONNECTICUT: 
The Center for Advanced Reproductive Services 
 The University of Connecticut Health Center 
263 Farmington Avenue 
 Dowling South Building, 3rd Floor 
 Farmington CT 06030-6224 
 860-679-4580 
Yale Reproductive Endocrinology and Infertility 
 150 Sargent Drive, 2nd Floor 




Brigham & Women’s Hospital Center for Assisted Reproduction 
 75 Francis St. 
 3rd Floor, ASB1-3 
 Boston, MA 02115 
 617-732-4222 
Massachusetts General Hospital Fertility Center 
 32 Fruit Street 
 Yawkey Suite 10A 




Columbia University Center for Women’s Reproductive Care 
 1790 Broadway, Second Floor 




Appendix B:  Consent Form 
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN 
HOSPITAL 
 
Study Title:  Tender Loving Care and the Woman with a History of Recurrent 
Pregnancy Loss 
Principal Investigator:  Pinar Kodaman, MD and Emily Gruetzmacher, PA-SII 
Funding Source:  To be determined 
 
Invitation to Participate and Description of Project 
 
You are invited to participate in a research study designed to look at the impact of 
increased first trimester care (tender loving care or TLC) on pregnancy outcome in 
pregnant women with a history of early first trimester recurrent pregnancy loss (RPL). You 
have been asked to participate because you are between the ages of 18 and 39 and you have 
a history of two or more consecutive first trimester clinical pregnancy losses. 
Approximately 267 pregnant women with RPL will participate in the study. The study will 
take place at five institutions within the Society for Assisted Reproductive Technology 
network. 
 
The primary outcome of the study will be the presence of an ongoing viable 
pregnancy at 12 weeks of gestation, visualized by transvaginal ultrasound. Secondary 
outcomes include first trimester bleeding, ectopic and molar pregnancies, subsequent 
spontaneous abortion (miscarriage), and termination of pregnancy. Levels of psychological 
distress will also be assessed as a secondary outcome measure. Psychological distress will 
be measured using the Edinburgh Depression Scale (EDS) at the beginning and end of your 
participation in the study. 
 
In order to decide whether or not you wish to be a part of this research study, you 
should know enough about its risks and benefits to make an informed decision. This 
consent form gives you detailed information about the research study, which a member of 
the research team will discuss with you. This discussion should go over all aspects of this 
research:  its purpose, the procedures that will be performed, any risks of the procedures, 
possible benefits, and possible alternative treatments. Once you understand the study, you 
will be asked if you wish to participate; if so, you will be asked to sign this form. 
 
Description of Procedures 
 
1. If you consent to participate in the study, you will meet with a clinician who 
will ensure that you are eligible for the study. The clinician will ask you 
questions about demographics (age, ethnicity, etc.), your medical history, and 
your obstetric history. The clinician will also perform a physical exam. 
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2. If you remain eligible for participation in the study, you will be asked to contact 
the institution immediately upon becoming pregnant. At this time, you will 
present to the institution and a medical assistant (MA) will draw a small amount 
of blood to confirm that you are pregnant by the presence of a pregnancy marker 
in your blood called human chorionic gonadotropin (hCG). You will also be 
asked to complete the EDS at this time, which will serve as a measurement of 
your level of psychological distress. 
3. Patients that become pregnant will then be randomly placed in two different 
groups by a computer-generated randomization system. One group will receive 
TLC during the first trimester of pregnancy and one group will receive standard 
prenatal care. 
4. If you are randomly assigned to the TLC group, you will receive an increased 
level of prenatal care during the first trimester of pregnancy. This will include:  
frequent blood draws after a positive pregnancy test to ensure that the level of 
hCG is rising appropriately (this will occur until about the fifth week of 
pregnancy), weekly transvaginal ultrasounds from the fifth week of gestation 
until the twelfth week of gestation, continuity of care with the same medical 
staff at each visit to the clinic, reassurance regarding the progression of your 
pregnancy, and the availability of a social worker for counseling purposes at 
each office visit. You will be encouraged to bring your partner with you to your 
visits. At the beginning of the TLC care, you will receive a form outlining each 
of your visits to the office so that you know what to expect during the study 
intervention period. You will also be asked to notify your standard OB-GYN of 
your pregnancy to establish routine prenatal care. 
5. If you are randomly assigned to the standard prenatal care group, you will be 
asked to notify your standard OB-GYN practitioner of your pregnancy. You 
will follow the prenatal care instructions and appointment schedule of your OB-
GYN practitioner. 
6. All women participating in the study will present to their respective institution 
at five weeks of gestation for a transvaginal ultrasound. This ultrasound will 
confirm the presence of a clinical pregnancy (a pregnancy that can be seen on 
ultrasound). All women will also return to the clinic at 12 weeks of gestation 
for another transvaginal ultrasound to assess pregnancy outcome, which will be 
the presence or absence of an ongoing viable clinical pregnancy. At this office 
visit, all women will be asked to complete another EDS to measure 
psychological distress. 
7. Your participation in the study will end at the completion of the first trimester 
of pregnancy (12 weeks of gestation). 
8. All information that is collected during the study that impacts your health will 
be reported to you and recorded in your medical record. 
 
Risks and Inconveniences 
 
 We would like for you to be aware of some risks and inconveniences associated 
with this study. Participation in the study will require transvaginal ultrasounds, during 
which you may experience a small amount of discomfort. This should resolve immediately 
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following the exam and you will be able to return to your normal daily activities following 
your office visits. The transvaginal ultrasounds will not pose a threat to your developing 
pregnancy. Participation in the study will also require blood work, during which a very 
small amount of blood will be drawn. This may result in discomfort at the site of needle 




Participation in this study may result in a number of health benefits, including 
improved pregnancy outcome and a decreased level of psychological distress. In addition 
to the health benefits impacting you directly, this study may also benefit other women with 
a history of RPL by helping to define the most effective way to manage patients such as 




 During the study, you will receive routine prenatal care from your standard OB-
GYN provider. You will be responsible for any co-pays required by your insurance 
company for the standard prenatal care. The additional prenatal care and testing that you 
may receive as a part of your participation in this study will be at no cost to you. You will 








Any identifiable information that is obtained in connection with this study will 
remain confidential and will be disclosed only with your permission or as required by U.S. 
or State law. Examples of information that we are legally required to disclose include abuse 
of a child or elderly person, or certain reportable diseases. The study protocol will be in 
compliance with current Health Insurance Portability and Accountability Act (HIPAA) 
regulations. To protect the confidentiality of the study participants, all data from the study 
will be labeled with unique patient identification numbers. All identifiable patient 
information, including names, addresses, dates of birth, and medical histories will be kept 
secure. Records and study data will be kept in locked cabinets and on encrypted and 
password protected computers. When the results of the research are published or discussed 
in conferences, no information will be included that would reveal your identity unless your 
specific consent for this activity is obtained. 
 
Representatives from the Yale Human Research Protection Program, the Yale 
Human Investigation Committee (the committee that reviews, approves, and monitors 
research on human subjects) may inspect study records during internal auditing procedures. 
However, these individuals are required to keep all information confidential. 
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In Case of Injury 
 
If you are injured as a result of your participation in the study, seek treatment and 
contact the study doctor as soon as you are able. Yale School of Medicine and Yale New 
Haven Hospital do not provide funds for the treatment of research-related injury. If you 
are injured as a result of your participation in this study, treatment will be provided. You 
or your insurance carrier will be expected to pay the costs of this treatment. No additional 
financial compensation for injury or lost wages is available. You do not give up any of 
your legal rights by signing this form. 
 
Voluntary Participation and Withdrawal 
 
Participating in this study is voluntary. You are free to choose not to take part in 
this study. Refusing to participate will involve no penalty or loss of benefits to which you 
are otherwise entitled (such as your health care outside the study, the payment for your 
health care, and your health care benefits). However, you will not be able to enroll in this 
research study and will not receive study procedures as a study participant if you do not 
allow use of your information as part of this study. 
 
If you do become a subject, you are free to stop and withdraw from this study at 
any time during its course. To withdraw from the study, you can call a member of the 
research team at any time and tell them that you no longer want to take part.  This will 
cancel any future appointments. The researchers may withdraw you from participating in 
the research if necessary, for example if you experience an adverse pregnancy event, such 
as miscarriage, ectopic and molar pregnancies, or termination of pregnancy. 
 
Withdrawing from the study will involve no penalty or loss of benefits to which 
you are otherwise entitled. It will not harm your relationship with your own doctors or with 
the Yale Fertility Center. The Yale Fertility Center will still treat you at your request or 
refer you to a clinic or doctor who can manage your care. 
 
When you withdraw from the study, no new health information identifying you will 
be gathered after that date. Information that has already been gathered may still be used 
and given to others until the end of the research study, as necessary, to insure the integrity 




  We have used some technical terms in this form. Please feel free to ask about 
anything you don't understand and to consider this research and the consent form 





I have read (or someone has read to me) this form and have decided to participate in the 
project described above. Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction. My signature 





      










Signature of Principal Investigator  Date 
  
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator, Pinar Kodaman, MD, or the co-PI, Emily 
Gruetzmacher, PA-SII, at (203) XXX-XXXX. 
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919 If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 
contact the Yale Human Investigation Committee at (203) 785-4688. 
 
THIS FORM IS NOT VALID UNLESS THE FOLLOWING BOX 
HAS BEEN COMPLETED BY THE HIC OFFICE 
 
 









Appendix C:  Letter to Study Institutions 
 
Dear medical staff at (name of institution), 
 
This letter is to inform you of an upcoming randomized controlled trial (RCT) 
assessing the difference in rates of successful pregnancy outcome at 12 weeks of 
gestation in women with a history of early recurrent pregnancy loss (RPL) who receive 
increased care (tender loving care or TLC) during the first trimester when compared with 
women who receive standard prenatal care during the first trimester. The study will take 
place at your institution and five other institutions within the Society for Assisted 
Reproductive Technology network. 
 
RPL (the loss of two or more consecutive pregnancies) affects about one to five 
percent of couples. This is traumatic for many women and has significant psychological 
implications, which can persist even after the birth of a healthy child. Studies have shown 
that increased monitoring and support (TLC) from a dedicated team of healthcare 
providers during subsequent pregnancies can improve pregnancy outcomes in women 
with a history of RPL. Women with RPL also report that they want this increased care 
from their providers. Although the results of studies examining the impact of TLC on 
pregnancy outcomes in women with RPL are compelling, questions remain regarding the 
efficacy of TLC. In addition, the impact of TLC on levels of psychological distress in this 
patient population is not well understood. A RCT is needed to determine if TLC does in 
fact improve pregnancy outcomes in RPL patients by reducing the rate of spontaneous 
abortion (SAB) and if TLC has an impact on levels of psychological distress in this 
population. 
 
Participant eligibility criteria: 
Inclusion criteria: 
• Women with a history of early RPL (two or more consecutive clinical pregnancy 
losses during the first trimester of pregnancy; clinical pregnancies are defined as 
pregnancies confirmed by ultrasound or histopathologic evaluation) 
• Aged 18-39 
• In patients with a history of prior live birth, the two most recent pregnancies must 
have ended in pregnancy loss 
• Women with known and unknown etiologies for RPL (women with known 
etiologies may receive treatment prior to or during study enrollment; those with 
unknown etiologies must not be receiving empiric treatment) 
Exclusion criteria: 
• History of psychiatric illness 
• Uncontrolled chronic disease (neurologic, cardiac, pulmonary, renal, and 
gastroenterology conditions) 
• Uncontrolled endocrine disorders (diabetes and hypo-/hyperthyroidism) 
• History of thrombophilia or venous thromboembolism 
• BMI <18.50 kg/m2 or ≥30 kg/m2  
• Conception by in-vitro fertilization or artificial insemination 
• Participation in another clinical study 
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• Inability to abstain from tobacco and alcohol and consume less than 200 mg of 
caffeine per day during participation in the study 
 
Patients that meet the eligibility criteria will be asked if they would like to participate 
in this study. Those who consent to participate will be screened through the completion 
of a baseline characteristics form and a physical exam. Those who remain eligible for the 
study will be asked to contact their respective institution upon becoming pregnant. At this 
time, women will present to the institution for confirmation of pregnancy through serum 
human chorionic gonadotropin (hCG) measurement. After pregnancy confirmation, 
women will be randomly assigned to receive TLC or standard prenatal care. TLC will 
include continuity of care from the same healthcare providers and serum hCG 
measurements every two days following a positive initial pregnancy test until a threshold 
of 2,000 mIU/ml or greater is reached. After that, TLC will include weekly transvaginal 
ultrasounds from five to twelve weeks of gestation, the availability of a social worker at 
each visit, and the involvement of each patient’s partner in the office visits. The primary 
outcome measure will be the presence or absence of a viable clinical pregnancy at 12 
weeks of gestation, as visualized on transvaginal ultrasound. Women will also complete 
the Edinburgh Depression Scale (EDS) at the beginning and end of the study period. The 
EDS will be used to measure psychological distress in order to assess the impact of TLC 
on levels of psychological distress in patients with a history of RPL. 
 
Your participation in this study will be greatly appreciated. We will need help with 
recruiting patients for the study. If you have patients that you think may be eligible for 
study participation, we ask that you notify your institution principal investigator (PI). We 
will need clinicians to provide TLC to participants in the study. We ask that these 
clinicians be willing to exhibit empathy and support when interacting with these patients 
during their TLC office visits. We will also need clinicians that are blinded to the study 
groups at each site to assess clinical pregnancy status by transvaginal ultrasound and 
score the EDS. A meeting will be held at your institution on (date) to provide the staff 
with more information and answer any questions. Please contact the study PI and/or co-PI 
if you have any questions or concerns (contact information below). 
 
Thank you very much for your time and for considering involvement in this study. 




Pinar Kodaman, MD 
Principal Investigator 
And 

















If you are between the ages of 18 and 39 and have a history of 
early recurrent pregnancy loss (2 or more consecutive first 
trimester pregnancy losses), you may be eligible for participation 
in a clinical study. 
 
We are studying the impact of increased first trimester care on 
pregnancy outcomes and levels of psychological distress in women 
with a history of early recurrent pregnancy loss. 
 
Please contact the institution principal investigator at (name of 
institution) at (phone number) if you have more questions and/or 
would like to participate. 
 
You may also contact the study PI, Pinar Kodaman, MD, or co-PI, 





Appendix E:  Baseline Characteristics Form 
 
Participant ID:  _______________           Date:  _______________ 
 
Age:  _______________ 
Height:  _______________ 
Weight:  _______________ 
 
Physical Exam performed? Yes     or     No 
 
Please circle the following: 
 
Age category (TO BE COMPLETED AT RANDOMIZATION): 
 18-24          25-29          30-34          35-39 
 
Ethnicity: 
Hispanic or Latino 
American Indian or Alaska Native 
Asian 
Black or African American 




 Married          Not Married 
 
BMI: 
 Normal Weight (18.50-24.99 kg/m2)          Overweight (25.00-29.99 kg/m2) 
 
Known vs. Unknown Etiology for RPL: 
 Known          Unknown 
 
Primary vs. Secondary RPL: 
 Primary          Secondary 
 
Numerical Category of Previous Losses: 




Appendix F:  TLC Form for Patients 
 
Dear Study Participant, 
You have been randomly assigned to the TLC group. A medical assistant (MA) and the 
scheduling staff at your institution will complete this form. All TLC office visits will be 
outlined below. Until about the fifth week of your pregnancy, you will come to the office 
every two days for blood samples to be drawn. This will monitor the hCG (pregnancy 
marker) in your blood to ensure that it is rising appropriately. Starting at week five of 
your pregnancy, you will come to the office once a week for a transvaginal ultrasound. At 
each office visit you will have the opportunity to ask questions or address any concerns 
that you might have. In addition, please take note of the following: 
• You will see the same clinician (MD or PA) and MA at each of your 
appointments. 
• Your partner is encouraged to come to each office visit with you to participate in 
the TLC care. Your partner will also have the opportunity to ask questions and 
engage in conversation. 
• A social worker will be available at each visit. Please feel free to utilize this 
resource at any time if you so desire. 
• Please notify your general OB-GYN practitioner of your pregnancy. Please attend 
appointments with them as scheduled and follow their advice regarding routine 
prenatal care. 
• Please notify the office if you experience any bleeding or if you have any 
questions or concerns. 
Thank you for your willingness to participate in this study. You will receive TLC until 
the completion of your first trimester of pregnancy (12 weeks of gestation). 
 
To be completed by MAs and scheduling staff: 
 
Your clinician:  ____________________ 
Your MA:  ____________________ 
Your social worker:  ____________________ 




Please see the reverse side of this form for your appointment dates. 
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hCG monitoring appointments (every 2 days following a positive pregnancy test until a 
hCG threshold of 2,000 mIU/ml or greater is reached): 

















Transvaginal ultrasound appointments (from 5 weeks of gestation until 12 weeks of 
gestation): 











Appendix G:  TLC Data Collection Form 
 
Participant ID:  ____________________ 
 
Participant’s clinician:  ____________________ 
Participant’s MA:  ____________________ 
Participant’s social worker:  ____________________ 
 
hCG monitoring appointments: 
Date of Appointment hCG Level Did patient’s 
partner attend the 
visit? (yes or no) 
Did patient see 
social worker? 
(yes or no) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Transvaginal ultrasound appointments: 
Date of 
Appointment 





the visit? (yes or 
no) 
Did patient see 
social worker? 
(yes or no) 
    
    
    
    
    
    
    




Please record any additional patient phone calls or office visits below: 
Date of Call or Visit Reason for Call or Visit (please indicate if patient called 




















































Appendix H:  EDS and Scoring Scale 
 
Edinburgh Depression Scale (EDS) 
 
Patient ID: ______________________________ 
 
As you are pregnant, we would like to know how you are feeling. Please check the 
answer that comes closest to how you have felt IN THE PAST 7 DAYS, not just how you 
feel today. 
 
Here is an example, already completed. 
 
• I have felt happy: 
☐Yes, all the time 
☐Yes, most of the time 
☐No, not very often 
☐No, not at all 
This would mean:  “I have felt happy most of the time” during the past week. 
 
Please complete the other questions in the same way. 
In the past 7 days: 
 
1. I have been able to laugh and see the funny side of things: 
☐As much as I always could 
☐Not quite so much now 
☐Definitely not so much now 
☐Not at all 
 
2. I have looked forward with enjoyment to things: 
☐As much as I ever did 
☐Rather less than I used to 
☐Definitely less than I used to 
☐Hardly at all 
 
3. *I have blamed myself unnecessarily when things went wrong: 
☐Yes, most of the time 
☐Yes, some of the time 
☐Not very often 
☐No, never 
 
4. I have been anxious or worried for no good reason: 




☐Yes, very often 
 
5. *I have felt scared or panicky for no very good reason: 
☐Yes, quite a lot 
☐Yes, sometimes 
☐No, not much 
☐No, not at all 
 
6. *Things have been getting on top of me: 
☐Yes, most of the time I haven’t been able to cope at all 
☐Yes, sometimes I haven’t been coping as well as usual 
☐No, most of the time I have coped quite well 
☐No, I have been coping as well as ever 
 
7. *I have been so unhappy that I have had difficulty sleeping: 
☐Yes, most of the time 
☐Yes, sometimes 
☐Not very often 
☐No, not at all 
 
8. *I have felt sad or miserable: 
☐Yes, most of the time 
☐Yes, quite often 
☐Not very often 
☐No, not at all 
 
9. *I have been so unhappy that I have been crying: 
☐Yes, most of the time 




10. *The thought of harming myself has occurred to me: 





Administered/Reviewed by ________________________________ 
Date ______________________________ 
 
Source: Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development 
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of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 150:782-786 . 
Source: K. L. Wisner, B. L. Parry, C. M. Piontek, Postpartum Depression N Engl J Med vol. 347, No 3, 
July 18, 2002, 194-199 
 
Users may reproduce the scale without further permission providing they respect copyright by quoting the 
names of the authors, the title and the source of the paper in all reproduced copies. 
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Edinburgh Depression Scale (EDS) 
 
SCORING: 
Questions 1, 2, & 4 (without an *): 
Are scored 0, 1, 2 or 3 with top box scored as 0 and the bottom box scored as 3. 
 
Questions 3, 5-10 (marked with an *): 
Are reverse scored, with the top box scored as a 3 and the bottom box scored as 0. 
 
Maximum score:  30 
Possible Depression:  10 or greater 
Always look at item 10 (suicidal thoughts) 
 
Instructions for using the Edinburgh Postnatal Depression Scale: 
1. The mother is asked to check the response that comes closest to how she has been 
feeling in the previous 7 days. 
2. All the items must be completed. 
3. Care should be taken to avoid the possibility of the mother discussing her answers 
with others. (Answers come from the mother or pregnant woman.) 
4. The mother should complete the scale herself, unless she has limited English or 






Source: Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development 
of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 150:782-786 . 
Source: K. L. Wisner, B. L. Parry, C. M. Piontek, Postpartum Depression N Engl J Med vol. 347, No 3, 
July 18, 2002, 194-199 
 
Users may reproduce the scale without further permission providing they respect copyright by quoting the 
names of the authors, the title and the source of the paper in all reproduced copies. 
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Appendix I:  Patient Data Collection Form 
 
Participant ID:  ____________________ 
 
Data of Last Menstrual Period:  ____________________ 
Estimated Gestational Age at Initial hCG Visit:  ____________________ 
 
Initial hCG (confirmed pregnancy – positive or negative):  ____________________ 
 
Presence or Absence of Ongoing Viable Clinical Pregnancy at 5 Weeks of Gestation: 
Yes          No 
 
Presence or Absence of Ongoing Viable Clinical Pregnancy at 12 Weeks of Gestation: 
Yes          No 
 
EDS Score at Beginning of Study Period:  ____________________ 
 
EDS Score at End of Study Period:  ____________________ 
 
Multiple gestation pregnancy: 
 Yes          No 
 
Adverse Events (circle): 
• First Trimester Bleeding 
• Ectopic Pregnancy 
• Molar Pregnancy 
• Subsequent SAB 
• Termination of Pregnancy 
 
Did patient establish routine prenatal care with her standard OB-GYN clinician? (circle) 
 Yes     or     No 
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Appendix J:  Sample Size Calculation 
 
















0.70 121    
TLC 0.85 121    
Rate 
Difference 
-0.15 242 0.05 -0.25 -0.05 
 
Alpha = 0.050, Tails = 2, Power = 0.802 
Power computation:  Normal approximation (unweighted mean p) 
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